Amgen Inc., the world’s largest biotechnology company, will pay Japan’s Kyowa Hakko Kogyo Co. as much as $520 million for the rights to a medicine that is being developed for inflammation and cancer, the two firms said Thursday.
Amgen, based in Thousand Oaks, Calif., will pay Kyowa Hakko $100 million initially and as much as $420 million tied to the development of the medicine, a humanized monoclonal antibody known as KW-0761, the companies said.
Unable to view this article?
This could be due to a conflict with your ad-blocking or security software.
Please add japantimes.co.jp and piano.io to your list of allowed sites.
We humbly apologize for the inconvenience.